This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perrien, D. S. Articles by Gaddy, D. Search for Related Content PubMed PubMed Citation Articles by Perrien, D. S. Articles by Gaddy, D. Related Collections Calcium and Bone Metabolism Female Endocrinology

Bone Turnover across the Menopause Transition: Correlations with Inhibins and Follicle-Stimulating Hormone

Physiology and Biophysics (D.S.P., S.E.B., B.W., L.J.S., D.G.), Center for Orthopaedic Research, Orthopaedic Surgery (L.J.S., D.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205; and Mayo Clinic and Foundation (S.J.A., S.K.), Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: Dana Gaddy, Ph.D., Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 505, Little Rock, Arkansas 72205. E-mail: gaddydana{at}uams.edu.

Context: Longitudinal clinical studies demonstrate that increases in bone turnover that occur in perimenopausal women correlate better with elevated serum FSH than with changes in serum estradiol (E2). This perimenopausal rise in FSH is due to a selective decrease in ovarian inhibin B (InhB). Our previous demonstration that inhibins suppress both osteoblast and osteoclast development suggests that changes in serum inhibins may regulate osteoblast and osteoclast differentiation and thereby bone turnover, independent of changes in sex steroids.

Objective: The objective of this study was to determine whether decreased serum inhibin A (InhA) and InhB levels correlate with increases in markers of bone turnover in women across the menopause transition and to evaluate serum inhibins as better predictors of bone turnover markers across the menopause transition than FSH or bioavailable E2.

Design: We studied a cross-sectional age-stratified population sample of 188 pre- and postmenopausal women not using oral contraceptives or hormone replacement therapy (age, 21–85 yr).

Results: Serum InhA and InhB levels significantly correlated inversely with markers of bone formation and bone resorption in pre- and perimenopausal women and with markers of bone formation in postmenopausal women (InhA only). FSH was not significantly correlated with bone turnover in either pre- or postmenopausal women; however, FSH was significantly correlated with bone resorption (C-terminal collagen I cross-link) in perimenopausal women (age, 45–54 yr). Using multivariate analyses, serum InhA better predicted bone formation and resorption markers in premenopausal women than either FSH or bioavailable E2.

Conclusions: Decreases in inhibin levels across the menopause transition are associated with increasing bone turnover, regardless of changes in sex steroids or FSH.

This article has been cited by other articles:

				R. S. Pearsall, E. Canalis, M. Cornwall-Brady, K. W. Underwood, B. Haigis, J. Ucran, R. Kumar, E. Pobre, A. Grinberg, E. D. Werner, et al. A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity PNAS, May 13, 2008; 105(19): 7082 - 7087. [Abstract] [Full Text] [PDF]

				G. R. Williams Hypogonadal Bone Loss: Sex Steroids or Gonadotropins? Endocrinology, June 1, 2007; 148(6): 2610 - 2612. [Full Text] [PDF]

				D. S. Perrien, N. S. Akel, P. K. Edwards, A. A. Carver, M. S. Bendre, F. L. Swain, R. A. Skinner, W. R. Hogue, K. M. Nicks, T. M. Pierson, et al. Inhibin A Is an Endocrine Stimulator of Bone Mass and Strength Endocrinology, April 1, 2007; 148(4): 1654 - 1665. [Abstract] [Full Text] [PDF]

				J. Iqbal, L. Sun, T. R. Kumar, H. C. Blair, and M. Zaidi Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation PNAS, October 3, 2006; 103(40): 14925 - 14930. [Abstract] [Full Text] [PDF]

				P. R. Ebeling Inhibin in bone--new tricks for an old dog. J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1669 - 1670. [Full Text] [PDF]